Notably, venetoclax-induced killing of CLL cells was dramatically enhanced even with low concentrations of MCL1i in all patient samples (Figs. 6B, C, D), suggesting that MCL1 limits the action of venetoclax against CLL cells. This evidence concerns the gene MCL1 and B-cell chronic lymphocytic leukemia.